A5102908869- Hemophilia Treatment and Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Platelet Disorders and Treatments
- Organ Transplantation Techniques and Outcomes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood properties and coagulation
- Dialysis and Renal Disease Management
- Blood donation and transfusion practices
- Safe Handling of Antineoplastic Drugs
- Immunotherapy and Immune Responses
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Practices and Patient Outcomes
- Organ Donation and Transplantation
- Infection Control in Healthcare
- Acute Kidney Injury Research
- Cardiac Arrhythmias and Treatments
- Patient Safety and Medication Errors
- Cerebrospinal fluid and hydrocephalus
- Blood groups and transfusion
- Chronic Myeloid Leukemia Treatments
- Pharmacy and Medical Practices
- Forensic Toxicology and Drug Analysis
- Infection Control and Ventilation
Hôpital Cochin
2001-2024
Assistance Publique – Hôpitaux de Paris
2001-2024
University of California, San Francisco
2022-2023
Saint Laurent Polyclinique
2018-2019
Société Française de Cardiologie
2015
Centre Hospitalier Universitaire de Rennes
2012
Établissement Français du Sang
2012
Institut Gustave Roussy
2006
PURPOSE To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND METHODS Patients, predominantly men, their CSSCs’ immunohistochemically determined programmed death-ligand 1 (PD-L1) status (tumor proportion score threshold, 1%), received (200 mg every 3 weeks). The primary endpoint was the 39-patient cohort’s objective response rate at week 15 (ORR W15 ). Secondary objectives were best ORR,...
9534 Background: Patients (pts) with advanced squamous cell carcinoma of the skin (SCCS) have a poor prognosis. Response rate (RR) 46% an anti PD-1 (REGN2810) was recently shown in 25 pre-treated pts. CARSKIN is open-label, phase II study evaluating pembrolizumab (Pembro) unresectable SCCS. We report preliminary efficacy and safety findings. Methods: Chemotherapy naive pts who had SCCS, ECOG PS < 2 were eligible. Baseline PD-L1 expression centrally assessed on tumor. Pembro kindly provided...
9547 Background: Cemiplimab, a PD-1-axis blocking agent, has recently been approved for unresectable cSCCs. We report results of the CARSKIN study evaluating pembrolizumab in first-line setting. Methods: Chemotherapy naive patients (pts) with cSCCs, either locally or regionally advanced metastatic, and ECOG PS ≤1 were accrued to this multi-institutional phase II trial assess tumor response rate (RR) safety administered IV (200 mg Q3W) period up 24 months (mo). Baseline PD-L1 expression was...
Blanot, Stephane; Gillon, Marie Christine; Lopez, Isabelle; Ecoffey, Claude Author Information
Background Rh proteins and the Wr b antigen, which results from an interaction between B 3 glycophorin A , are most common targets for warm immunoglobulin ( Ig ) G autoantibodies. Apart autoanti‐ Di a scarce specificity, IgG autoantibodies specific have never been characterized by serologic methods. Study Design Methods Blood samples 120 patients with autoimmune hemolytic anemia AIHA ‐coated red blood cells RBC s) were studied Some investigated immunochemical Results Autoantibodies against...
Importance In adults, treatment at profit dialysis facilities has been associated with a higher risk of death. Objective To determine whether status is the death in children kidney failure treated and any such association mediated by differences access to transplant. Design, Setting, Participants This retrospective cohort study reviewed US Renal Data System records 15 359 who began receiving for between January 1, 2000, December 31, 2019, facilities. The data analysis was performed May 2,...
Background Use of eGFR to determine preemptive waitlisting eligibility may contribute racial/ethnic disparities in access waitlisting, which can only occur when the falls ≤20 ml/min per 1.73 m 2 . an alternative risk-based strategy for reduce these inequities ( e.g. , a kidney failure risk equation [KFRE] estimated 2-year failure) rather than standard threshold determining waitlist eligibility. Our objective was model amount waittime that could be accrued by race and ethnicity, applying two...
Cortactin is an F-actin-binding protein expressed in platelets. During aggregation by thrombin, cortactin associates with Src, tyrosine phosphorylated, and then translocates to the cytoskeleton. It also found associate Syk during platelet shape change. Since undergoes phosphorylation platelets activated thrombopoietin (TPO) that exhibit neither change nor aggregation, we investigated whether it could relocalize detergent-insoluble fraction. We demonstrate was present as a...
TPS9596 Background: Treatment options are limited for patients (pts) with locally advanced or metastatic cSCCs. Cisplatin-based combinations have some efficacy but their toxicity often prohibits use, particularly the elderly. New therapeutic needed. Tumors divert programmed death receptor 1 (PD-1) pathway suppressing immune control. Pembrolizumab (MK-3475) is a high-affinity humanized monoclonal anti-PD-1 antibody. It leads to dual PD-1 ligand (PD-L1 and PD-L2) blockade that may reactivate...
Summary. The aims of the study were to evaluate impact a written information about treatment related risks in patient receiving blood derived or recombinant medications. Haemophiliac patients and with constitutional acquired immune deficiencies are concerned by this these information. Our objectives efficacy information, knowledge medications psychological, emotional if is based on questionnaires which specified how treat bleeding episodes, their viral safety products, patient's perception...
<title>Abstract</title> Medication adherence following transition to emicizumab in patients with severe hemophilia A: results of a longitudinal observational multicenter real-life study Background Hemophilia A (HA) is rare X-linked congenital bleeding disorder characterized by deficiency coagulation factor VIII (FVIII). Treatment traditionally involves regular intravenous injections clotting concentrates. Recent advances, such as extended half-life FVIII and the subcutaneous non-factor...
Cortactin is an F-actin-binding protein expressed in platelets. During aggregation by thrombin, cortactin associates with Src, tyrosine phosphorylated, and then translocates to the cytoskeleton. It also found associate Syk during platelet shape change. Since undergoes phosphorylation platelets activated thrombopoietin (TPO) that exhibit neither change nor aggregation, we investigated whether it could relocalize detergent-insoluble fraction. We demonstrate was present as a...